ABSTRACT The full primary structure of the very potent opioid peptide dynorphin, from porcine pituitary, has been determined. It is (H)Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-LysLeu-Lys-Trp-Asp-Asn-Gln(OH). The synthetic peptide with this sequence behaves identically to natural dynorphin in a number ofways, and it has the same potency in the guiinea pig ileum myenteric plexus-longitudinal muscle bioassay. The potency is accounted for by the first 13 residues.
Dynorphin is an extremely potent opioid peptide which contains [Leu]enkephalin as its NH2-terminal sequence. Originally isolated in small amount from a commercial porcine pituitary preparation, its amino acid sequence could be determined with certainty only through the 13th residue [Tyr-Gly-Gly-Phe-LeuArg-Arg-Ile-Arg-Pro-Lys-Leu-Lys] (1) . Antisera to synthetic dynorphin-(1-13) were then developed for a highly specific and sensitive radioimmunoassay, with which it has been determined that dynorphin is a widely distributed neuropeptide (2) (3) (4) and evidently interacts in vivo with its own unique type of opiate receptor (5, 6) . By using this radioimmunoassay as a guide to purification, and with the aid of an immunoaffinity procedure, we have now isolated biologically active dynorphin from porcine pituitary in sufficient amount to establish the entire amino acid sequence.
MATERIALS AND METHODS
In the radioimmunoassay (7) , synthetic dynorphin-(1-13) (Peninsula Laboratories, San Carlos, CA) was used as the standard for measurement of immunoreactive dynorphin (ir-dynorphin). Bioassay used the guinea pig myenteric plexus-longitudinal muscle preparation as described (8, 9) . Protein was determined by the Lowry procedure (10) with bovine serum albumin as standard. Amino acid analysis at Palo Alto used standard routines and "Hi-Phi" buffer systems with the Dionex (Sunnyvale, CA) amino acid analyzer kit. Amino acid analysis at Pasadena was carried out on the Durrum D-500 analyzer. Sequence determinations were carried out as described (11) .
Two sources ofdynorphin were used. The first was the same melanotropin concentrate (MC) from which dynorphin was previously obtained (1) . This powder is a dried oxycellulose adsorbate of an extract of whole porcine pituitaries, generously furnished by J. D. Fisher (Armour, Kankakee, IL). Several 20-g batches were processed. The second source was 2500 lyophilized porcine posterior pituitaries (i.e., neurointermediate lobes; PP), purchased from Pel-Freez. Dynorphin from both sources was isolated in a pure state in five steps. Table 1 summarizes the amounts processed, yields, and specific activities at each step.
Step 1. Extraction. Dry PP or MC material was weighed, pulverized, and then extracted in boiling acetic acid (0.1 M or 1.0 M, 50 ml/g) for 30 min with stirring. This solvent yields more ir-dynorphin than the acidified methanol used previously.
After centrifugation (8000 x g, 40 min, 20C) the supernatant solution was removed, and the pellet was resuspended in cold acetic acid and centrifuged again. The yield from PP was the same with either concentration of acetic acid, but 1.0 M was required for maximal yield from MC.
Step 2a. CM-Sephadex batch procedure. This desalting step was not required for PP extracts. Extracts and wash solutions containing MC material were loaded onto CM-Sephadex (Pharmacia, C-25, prewashed with 1.0 M acetic acid, 1 g per g of MC starting material). After washes with 1.0 M acetic acid and then water (300 ml each), the material was eluted with MeOH/0.3 M HCl, 1:1 (vol/vol), at room temperature. The eluate was diluted with 2 vol of0.1 M acetic acid. Subsequent procedures were identical for PP and MC.
Step 2b. Precipitation. The 0.1 M acetic acid solution was adjusted to pH 8.6 with NH40H. The precipitate that was formed represented 10-20% ofthe total ir-dynorphin for PP and 60-70% for MC. After the precipitate was dissolved in MeOH/ HC1 and reprecipitated, gel permeation analysis on Sephadex G-50 showed that the precipitate contained a 3-kilodalton (kDal) immunoreactive material, whereas the 1.7-kDal ir-dynorphin remained in solution. The pH 8.6 precipitates were set aside for future study. To the supernatant solution, now 0.1 M in ammonium acetate at pH 8.6, was added Triton X-100 (Calbiochem) to 0.1%.
Step 3. Cation exchange. This step takes advantage of the strongly basic character of 1.7-kDal dynorphin, evident from the three arginine and two lysine residues of the dynorphin-(1-13) sequence. The solution from step 2b was loaded onto a preequilibrated CM-Sephadex column and eluted by a linear gradient of ammonium carbonate (0.1-1.0 M) at pH 8.6 (Fig.  1) . A prominent peak of ir-dynorphin was eluted at 0.4 M ammonium carbonate. Results with PP and MC at this step were virtually identical, and 100-to 400-fold purifications were typical.
Step 4a. Immunoextraction. "Lucia" antiserum, with affinity in the low picomolar range (7), has been used to measure irdynorphin in tissues (2, 4) . Two steps were used to obtain a useful immunoaffinity resin. First, synthetic dynorphin-(1-13) was coupled to cyanogen bromide-activated Sepharose 4B in order to obtain affinity-purified antibodies from the antiserum (12 Purification of dynorphin from PP by cation exchange. Supernatant solution from step 2 (500 ml, pH 8.6) was passed through a CM-Sephadex column (2 x 50 cm, equilibrated at 40C with 0.1 M ammonium carbonate in 0.1% Triton X-100, 100 ml/hr, 10,ml fractions). A, sample loading; B, 500-ml wash with same buffer; C, start of linear gradient (800 ml) to 1.0 M ammonium carbonate in 0.1% Triton X-100. No more ir-dynorphin was eluted by washing column with water and then 1.0 M HCl. Each fraction was assayed for protein (broken line) and ir-dynorphin (solid line). Major peak of ir-dynorphin, which was eluted at 0.4 M ammonium carbonate, contained 46% (16.7 nmol) of the initial ir-dynorphin and 0.25% (1.91 mg) of the initial protein.
Overall recoveries: ir-dynorphin, 76% (29.1 nmol); protein, 94% (756 mg). a different rabbit had properties apparently identical to those of "Lucia," and an affinity resin prepared with it was used sometimes.
The pooled fractions from step 3 containing ir-dynorphin were subdivided for immunoextraction with batches of resin (capacity, 15-30 nmol in 1-2 ml). Incubation was carried out at 40C overnight, with shaking. Resin was then washed with 200 ml of 0.15 M sodium phosphate (pH 7.4) containing 5% Triton X-100, then with the same volume of phosphate buffer alone, and finally with water. After the overnight incubation, no irdynorphin remained in solution; 5-10% was detectable in the washes, mostly in the Triton X-100 wash. The peptide was eluted with three 10-ml portions of 0.5 M acetic acid (each for 30 min, 37C). Overall recovery at step 4a was 60-65% for PP and 55-60% for MC, but the degree of purification is unknown because total protein in the eluate was below the limit of detection by absorbance, and we were unwilling to commit any significant fraction of the material to a destructive assay procedure.
Step4b. Concentration by CM-Sephadex adsorption. The 0.5 M acetic acid eluate was applied to CM-Sephadex in a small column (0.5 ml packed volume, prewashed with 50 ml each of 1.0 M HC1, 1.0 M NaOH, and MeOH/HCl). The adsorbed peptide was eluted with 2 ml of MeOH/HCl.
Step 5. High-performance liquid chromatography (HPLC). Portions (1 ml) of the MeOH/HCl eluate from step 4b were injected onto a reverse-phase HPLC column. Fig. 2 shows a typical elution diagram for PP material; an identical result was obtained with MC material. A single symmetrical peak of irdynorphin and absorbance was eluted at exactly the same position as the major peak ofir-dynorphin in a crude MeOH/HCl extract of starting material (not shown), indicating that fragmentation or derivatization did not occur during purification.
Proc. Nad Acad. Sci A second and steeper gradient, from 35% to 90% acetonitrile in 10 min (not shown), yielded no more ir-dynorphin. The elution position of natural dynorphin shows that it is more hydrophobic than the synthetic tridecapeptide. Fractions containing ir-dynorphin were pooled. Samples from this pool (both PP and   FIG. 3 . Bioassay of dynorphin: typical record in the bioassay of pure PP dynorphin (8, 9) . Electrically stimulated twitch of guinea pig longitudinal muscle occurs every 10 sec. (Upper) Dynorphin from step 5 (see Fig. 2 Fig. 3 . Absorbance was monitored at 254 and 228 nm. As expected, a single fragment absorbing at 254 nm was obtained from dynorphin-(1-13) (28.0% acetonitrile, A228/A2u = 23), which was assumed to be dynorphin-(1-6). Two such fragments were obtained from PP or MC dynorphin. One was identical to that from dynorphin-(1-13). The second fragment in each case was eluted earlier in the gradient (PP, at 23.6% acetonitrile; MC, at 23.8% acetonitrile) and had a different ratio ofabsorbances at the two wavelengths (PP, 10.6; MC, 10.4), as expected for a tryptophan-containing peptide. These fragments from PP and MC were collected from HPLC, frozen, and sent to Pasadena for sequence determination.
Carboxypeptidase A (Sigma, Type I, diisopropyl fluorophosphate-treated) was used to confirm the identity of the 
RESULTS AND DISCUSSION
In Fig. 3 , showing the bioassay ofpure dynorphin from step 5, the upper record depicts the slow reversal on washout (13) that is characteristic ofdynorphin; the lower record shows rapid and complete antagonism by 200 nM naloxone. Quantitative bioassay was carried out on seven such muscle preparations, each estimate of the concentration for 50% inhibition (IC50) being obtained by interpolation into the log(dose)-response curve for synthetic dynorphin-(1-13) obtained on the same preparation. The same solutions of PP dynorphin and dynorphin-(1-13) were diluted serially in MeOH/ HCl for parallel determinations in the radioimmunoassay, and aliquots were also taken for amino acid analysis. In the bioassay, IC50 of dynorphin-(1-13) standard was 270 ± 40 pM (mean + SEM), and the solution ofPP dynorphin had activity equivalent to 253 ± 34 pmoVml. Immunoreactivity of the PP dynorphin solution was found to be 273 pmoVml, referred to dynorphin-(1-13) standard. Thus, the specific biologic activity ofdynorphin (i.e., biologic activity/immunoreactivity) was 0.93 ± 0.12, relative to dynorphin-(1-13). Biologic activity entirely comparable to that shown in Fig. 3 was displayed also by MC dynorphin.
An aliquot of the same PP dynorphin was hydrolyzed in 6 M HCl (sealed tube, 1200C, 24 hr) and then subjected to amino acid analysis. The two prominent peaks of aspartic acid (two residues, see below) and phenylalanine (one residue) yielded estimates of 0.93 and 0.82 nmol of peptide, respectively. An identical aliquot subjected to radioimmunoassay contained 0.87 nmol with reference to dynorphin-(1-13) standard. Thus, there is complete equivalence of PP dynorphin and dynorphin-(1-13) with respect to both immunoreactivity and bioactivity, and radioimmunoassay measures the absolute amount of natural dynorphin.
Sequence determinations gave unambiguous results ( Table  2 ). The COOH-terminal tryptic fragment unexpectedly contained leucine-12 as its NH2-terminal residue. Thus, the Lys13-Trp'4 bond was resistant to digestion, although the identification of residue 13 as lysine was unequivocal. Although trypsinresistant lysyl bonds are rare, they have been reported. Review of all relevant sequences in ref. 14 revealed two instances in which a Lys-Trp bond was not attacked by trypsin (15, 16) and two other instances (17, 18) in which the expected tryptic dipeptide Leu-Lys was not produced when the leucine residue was in the NH2-terminal position, as it would be here iftryptic cleavage occurred first at lysine-li. Trypsin resistance ofLys13-Trp14 in dynorphin could reflect some peculiarity of secondary structure.
Amino acid composition analysis ( dynorphin-(1-13)-Ser-Asp-Asn-Gln(NH2), 4; dynorphin-(1-13)-Ser-Asp-Asn-Gln(OH), 827; PP dynorphin, 1257. These data are expressed as glutamine equivalents, and are corrected for amounts found in preincubation samples and for autodigestion in the absence of substrate. In the same incubations, the following data were obtained for aspartic acid (residue 15): -10, 94, and 139, respectively. Amino acid release after a 7-hr incubation was determined by a modified procedure that yielded separate peaks for serine, asparagine, and glutamine. The only amino acid that increased during this incubation was glutamine, from 52 to 368 pmol/ nmol of peptide.
We conclude that natural biologically active dynorphin terminates in a free carboxyl group, that the complete amino acid sequence is (H)Tyr-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-LysLeu-Lys-Trp-Asp-Asn-Gln(OH), and that dynorphin from PP is identical to that from MC.
Synthetic dynorphin with the above sequence was obtained from Peninsula Laboratories (>99% pure by thin-layer chromatography, electrophoresis, and HPLC) and compared with natural dynorphin. In the HPLC system described earlier, the elution position of the synthetic peptide was identical to that shown in Fig. 2 . Moreover, a mixture of synthetic and natural dynorphins coeluted as a single symmetrical peak of immunoreactivity. Tryptic fragments were also eluted at identical positions in HPLC; and they had the same amino acid compositions (including the anomalous leucine-12 and lysine-13), confirming the trypsin resistance ofthe Lys'3-Trp'4 bond in this peptide. Immunoreactivities ofsynthetic and natural dynorphin were the same and were identical to the immunoreactivity of dynorphin-(1-13). The ICw ofsynthetic dynorphin in the guinea pig ileum bioassay was 330 ± 60 pM (n = 11), indistinguishable from that of PP dynorphin or dynorphin-(1-13). Naloxone K., which is a measure of receptor selectivity (6, 19) , was 31 ± 2 nM (n = 6) for synthetic dynorphin and 30 ± 3 nM (n = 6) for dynorphin-(1-13).
The main improvements in the present procedure have been: (a) avoidance of lyophilization, a step that we find entails large losses; (b) use of detergents to minimize adsorptive losses; (c) monitoring by radioimmunoassay instead of bioassay; and (d) use of an immunoaffinity resin. The 17-residue length of dynorphin is close to that indicated by apparent Mr on Sephadex G-25 when pituitary opioid peptides were first discovered in this laboratory in 1975 (20) . We have here confirmed that the full biologic activity of this remarkably potent opioid peptide is determined by its first 13 residues. The functional significance of the remaining four residues is unknown; they might make the peptide more stable in vivo.
That dynorphin plays an important physiologic role is indicated by its potency, which is greater than that of any known endogenous opioid peptide, and by the existence of a highly specific dynorphin receptor in guinea pig myenteric plexus and brain (5, 6, 19) . This receptor is evidently the same as the opiate receptor called K, with which certain benzomorphans are known to interact preferentially.
